B CELL LYMPHOMA

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This study tests whether a combination of two drugs, zanubrutinib and rituximab, can control a dangerous immune condition called secondary hemophagocytic lymphohistiocytosis (HLH) that occurs in people with B-cell lymphoma. About 40 participants aged 14-80 will receive the treatm…

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can better control the cancer. About 36 adults with follicular lymphoma or diffuse large B-…

This early-phase trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified to better find and…

This study tests the safety and effectiveness of combining two drugs, rituximab and zanubrutinib, for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 participants will receive the drug combination, and researchers will measure how well the tumors shr…

This study tests whether combining two therapies—axicabtagene ciloleucel (a cell therapy) and glofitamab (a drug)—can help control large B cell lymphoma that came back or didn't respond to initial treatment. About 40 adults with this aggressive blood cancer will receive the combo…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like certain lymphomas) that have returned or stopped responding to standard therapy. The goal is to…

This early-phase trial tests a new drug called IKS03 in about 140 adults with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is designed to seek out and attack cancer cells while sparing healthy ones. The main goals are to find the safest d…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma who have not had prior therapy. The goal is to see how many patients achieve complete remission after 8 cycles. The treatment is ad…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to standard therapy. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from a donor, designe…

This early study is testing a new gene therapy (LCAR02) for people with B-cell lymphoma that has returned or not responded to standard treatments. Up to 18 participants will receive the therapy to see if it is safe and can shrink or eliminate tumors. The goal is to gather initial…

This study tests an experimental oral drug called LP-168 in adults with B-cell lymphoma that returned or didn't respond to standard treatments. The main goals are to find the safest dose and check if the drug can shrink tumors. About 200 participants will take the drug daily, and…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have blood samples taken to measure…